/stocks — the workspaceLOADING

CPIX · All filings · Read this filing

What changed 10-Q

Item 2. Unregistered Sales of Equity Securities

2021-05-14 compared with 2020-11-13 · 28 added, 16 removed, 25 unchanged (64% of the section changed)

3 unchanged sentences

In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.

The following table summarizes the activity, by month, during the three months ended September 30, 2020:

Purchased (1)

The following table summarizes the activity, by month, during the three months ended March 31, 2021:

Total Number of

8 unchanged sentences

Purchased Under

July 33,887 $ 3.31 33,887 $ 6,711,736

August 31,196 3.37 31,196 6,606,469

September 36,271 (1) 3.33 36,271 6,485,814

January 25,349 $ 3.23 25,349 $ 6,108,241

February 33,325 3.41 33,325 5,994,725

March 33,050 3.26 33,050 5,887,030

Total 91,724 91,724

(1) Of this amount, 1,324 shares were repurchased directly through private purchases at the then-current fair market value of common stock.

10.1* Third Amendment to Revolving Credit Note and Fourth Amendment to Revolving Credit Loan Agreement, dated as of October 7, 2020 by and between Cumberland Pharmaceuticals Inc.

and Pinnacle Bank .

10.1 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between A.J.

Kazimi and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.11 of the Registrant’s Annual Report on Form 10-K (File No.

001-33637) as filed with the SEC on March 12, 2021

10.2 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between Martian E.

Cearnal and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.12 of the Registrant’s Annual Report on Form 10-K (File No.

001-33637) as filed with the SEC on March 12, 2021

10.3 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between Leo B.

Pavliv and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.13 of the Registrant’s Annual Report on Form 10-K (File No.

001-33637) as filed with the SEC on March 12, 2021

10.4 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between Michael P.

Bonner and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.14 of the Registrant’s Annual Report on Form 10-K (File No.

001-33637) as filed with the SEC on March 12, 2021

10.5 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between James L.

Herman and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.15 of the Registrant’s Annual Report on Form 10-K (File No.

001-33637) as filed with the SEC on March 12, 2021

31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

2 unchanged sentences

Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS* XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.

101.SCH* XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

101.CAL* XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

101.DEF* XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

101.LAB* XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

101.PRE* XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

101.INS* INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.

101.SCH* INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

101.CAL* INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

101.DEF* INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

101.LAB* INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

101.PRE* INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

104 COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)

* Filed herewith.

2 unchanged sentences

Cumberland Pharmaceuticals Inc.

November 13, 2020 By:

May 14, 2021 By:

/s/ Michael Bonner

Michael Bonner

Chief Financial Officer

Chief Financial Officer and Duly Authorized Officer

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.